Core Viewpoint - WuXi AppTec (603259.SH, 02359.HK) announced a block trade to reduce its stake in WuXi Biologics (02268.HK) by 50.8 million shares, accounting for approximately 4.23% of WuXi Biologics' total share capital, with a transaction value of about HKD 2.178 billion [1][3]. Group 1: Share Reduction and Financial Impact - This marks the third reduction by WuXi AppTec since November 2024, with a cumulative reduction amounting to HKD 4.6 billion [3]. - The recent share reduction occurred when WuXi Biologics' stock price reached an all-time high [3]. - The investment gain from this reduction is approximately RMB 1.847 billion, representing over 10% of the projected net profit for 2024 [5]. Group 2: Strategic Response to Market Conditions - The global pharmaceutical outsourcing industry is facing intensified competition, with WuXi AppTec encountering multiple challenges from geopolitical and trade policies [5]. - Approximately 64% of WuXi AppTec's revenue is derived from the U.S. market, making it vulnerable to the impending "reciprocal tariff" policy, which could significantly impact its profitability [5]. - In response, WuXi AppTec is accelerating its global expansion, including the construction of a new facility in Middleton, USA, expected to be operational by the end of 2026 [5][6]. Group 3: Future Growth and Talent Acquisition - The funds raised from the share reduction will be primarily allocated to accelerate global capacity building, attract and retain top talent, and enhance its integrated CRDMO business model [5][6]. - WuXi Biologics, as the second-largest ADC CRDMO company globally, reported impressive performance in 2024, with revenues of RMB 4.052 billion, a year-on-year increase of 90.8%, and a net profit growth of 277.2% [6]. - The independent operation of WuXi Biologics allows it to focus on high-value areas such as ADC research and production, while WuXi AppTec can concentrate more resources on its core business, strengthening its leading position in the global pharmaceutical outsourcing market [6][7].

環境、社會及管治報告 2024 目錄 | 關於本報告 | 03 | | --- | --- | | 董事長兼首席執行官致辭 | 04 | | 2024 ESG 亮點績效 | 05 | | 2024 ESG 評級表現 | 06 | | 關於藥明康德 | | 賦能客戶 | | | --- | --- | --- | --- | | 我們的管治 | 09 | 產品與服務質量 | 38 | | | | 可持續供應鏈 | 42 | | ESG 管理策略 | | 守護地球 | | | ESG 治理 | 16 | 氣候變化 | 48 | | ESG 管理 | 18 | 排放管理 | 58 | | 重要性議題評估 | 20 | 資源管理 | 62 | | 責任公民 | | 社區共建 | | | 商業道德與合規 | 25 | 我們的員工 | 67 | | 反腐敗與反賄賂 | 29 | 我們的工作環境 | 73 | | 信息安全保護 | 32 | 我們的社區 | 76 | 79 86 績效表 附錄 關於藥明康德 ESG 管理策略 責任公民 賦能客戶 守護地球 社區共建 績效表 03 關於本報告 報告範圍及邊界 本報告中提供的政策 ...

2024 环境、社会及管治报告 目录 | 关于本报告 | 03 | | --- | --- | | 董事长兼首席执行官致辞 | 04 | | 2024 ESG 亮点绩效 | 05 | | 2024 ESG 评级表现 | 06 | | 关于药明康德 | | 赋能客户 | | --- | --- | --- | | 我们的管治 | 09 | 产品与服务质量 | | | | 可持续供应链 | | ESG 管理策略 | | 守护地球 | | ESG 治理 | 16 | 气候变化 | | ESG 管理 | 18 | 排放管理 | | 重要性议题评估 | 20 | 资源管理 | | 责任公民 | | 社区共建 | | 商业道德与合规 | 25 | 我们的员工 | | 反腐败与反贿赂 | 29 | 我们的工作环境 | | 信息安全保护 | 32 | 我们的社区 | | 38 | | --- | | 42 | | 48 | | --- | | 58 | | 62 | | 67 | | --- | | 73 | | 76 | 79 86 绩效表 附录 关于药明康德 ESG 管理策略 责任公民 赋能客户 守护地球 社区共建 绩效 ...

Financial Performance - In 2024, the company's revenue reached RMB 39,241.4 million, a decrease of 2.7% compared to RMB 40,340.8 million in 2023[12] - The net profit attributable to the parent company was RMB 9,352.6 million, down 12.5% from RMB 10,690.2 million in the previous year[12] - The company achieved operating revenue of RMB 39,241.4 million, a decrease of 2.7% year-on-year, with net profit attributable to shareholders at RMB 9,352.6 million, down 12.5%[14] - The adjusted net profit attributable to the parent company for the year ended December 31, 2024, was RMB 10,582.5 million, slightly down from RMB 10,854.6 million in 2023, with an adjusted gross profit of RMB 16,326.3 million, down from RMB 16,937.8 million, resulting in an adjusted gross margin of 41.6%[39] - The gross profit for 2023 was RMB 16,372,472 thousand, with a gross margin of 40.6%, up from 36.9% in 2022[97] Assets and Liabilities - The total assets increased to RMB 80,325.8 million, up from RMB 73,669.3 million in 2023, reflecting a growth of 9.0%[13] - The total liabilities increased to RMB 21,240.2 million, up from RMB 18,151.9 million in 2023[13] - Total liabilities rose to RMB 21,240.2 million as of December 31, 2024, from RMB 18,151.9 million in 2023, with a debt-to-asset ratio of 26.4%[33] - The company reported a decrease in goodwill to RMB 972.4 million as of December 31, 2024, down 46.6% from RMB 1,820.9 million in 2023, primarily due to reclassification to assets held for sale[40] Cash Flow and Financial Position - The company reported a cash and cash equivalents balance of RMB 13,434.3 million, significantly higher than RMB 10,001.0 million in the previous year[13] - Cash generated from operating activities was RMB 11,986.8 million, a decrease of 5.2% year-on-year, but excluding COVID-19 commercialization projects, it increased by RMB 2,100 million, or 22.1%[31] - The company reported a free cash flow of RMB 7,983.3 million for the year ended December 31, 2024, compared to RMB 7,124.7 million in 2023[31] - The company experienced a significant increase in tax receivables, which rose to RMB 87.2 million as of December 31, 2024, compared to RMB 17.5 million in 2023, marking a 397.4% increase[40] Business Growth and Market Position - The company achieved a record high of RMB 49.31 billion in backlog orders, representing a 47.0% year-on-year increase[9] - The company expects a revenue growth of 10-15% for its continuing operations in 2025[9] - The company anticipates a return to double-digit growth in continuing operations revenue in 2025, projecting a year-on-year increase of 10% to 15%[19] - Revenue from the top 20 global pharmaceutical companies reached RMB 16.64 billion, with a year-on-year growth of 24.1% excluding COVID-19 commercialization projects[14] - The chemical business generated revenue of RMB 29,052.4 million, with a year-on-year growth of 11.2% when excluding COVID-19 projects[16] Operational Efficiency and Strategic Initiatives - The company aims to enhance operational efficiency and expand globally to meet increasing customer innovation demands[9] - The company plans to enhance its production capacity, with the total volume of small molecule API reactors expected to exceed 4,000 kL by the end of 2025[58] - The company has doubled its oral formulation capacity at its Swiss facility during 2024[58] - The company is expanding its capabilities in various innovative technologies, including continuous flow purification and new drug formulation techniques[54] - The company aims to strengthen its global capabilities and scale to better empower pharmaceutical innovation[54] Governance and Management - The board consists of 12 members, including 5 executive directors, 2 non-executive directors, and 5 independent non-executive directors[101] - The company has a strong governance structure with a diverse board of directors and experienced management team, ensuring effective oversight and strategic direction[132] - The company has established a comprehensive internal control system to ensure compliance with laws and regulations, although risks remain due to the number of subsidiaries[88] - The company is committed to ensuring that the compensation for non-independent directors and senior management aligns with contractual terms and is fair and reasonable[181] - The company has received annual written confirmations of independence from all independent non-executive directors, affirming their status as independent individuals[150] Risks and Challenges - The company faces risks from potential declines in demand for pharmaceutical R&D services due to market trends or budget adjustments by clients[85] - Regulatory changes in the pharmaceutical R&D services industry may pose risks if the company cannot adapt its strategies accordingly[86] - The company faces intensified competition in the pharmaceutical R&D services market, particularly from large international pharmaceutical companies and new market entrants[87] Shareholder Returns and Incentives - A cash dividend of RMB 9.8974 per 10 shares was approved for distribution to shareholders listed on the register as of June 25, 2024[65] - The company decided to terminate the 2023 H-share incentive trust plan and plans to repurchase and cancel 15,467,500 H-shares[67] - The 2024 H-share incentive trust plan was approved, with a total of HKD 1 billion used to purchase 27,478,428 H-shares, accounting for approximately 0.94% of the total issued share capital[68]

4月2日晚，药明康德发布公告称，公司于4月1日通过大宗交易出售联营企业药明合联5080万股股票，占 其当前总股本的4.23%，成交金额约21.78亿港元。 药明康德表示，此次交易预计将为公司带来约18.47亿元人民币的投资收益，占2024年度经审计归母净 利润的10%以上，将显著提升2025年上半年业绩表现。本次减持后，药明康德子公司合全药业仍通过香 港子公司持有药明合联33.94%股份，保持第二大股东地位。 事实上，此次减持已经是药明康德半年内的第三次减持。药明康德曾于2024年11月及2025年1月通过两 次大宗交易累计出售8600万股，套现24.26亿港元。若叠加本次减持，三次交易合计减持比例达11.4%， 套现总额超46亿港元。 值得一提的是，药明康德的几轮减持，建立在药明合联股价不断上涨的背景下：自2023年11月登陆港交 所以来，药明合联的股价便持续攀升，4月1日盘中更是创下49.50港元的历史新高。 资料显示，药明合联成立于2021年，由药明生物与合全药业合资设立，主要从事抗体偶联药物 （ADC）等生物偶联药物的CRDMO服务，客户覆盖全球前20大药企中的13家。业绩方面，药明合联 2024年实 ...

Core Insights - The report highlights the ongoing recovery in the A-share market, with a focus on sectors such as technology, healthcare, and renewable energy, indicating a shift towards growth-oriented investments as the economy stabilizes [5][9][10]. Domestic Market Performance - The Shanghai Composite Index closed at 3,350.13 with a slight increase of 0.05%, while the Shenzhen Component Index closed at 10,513.12, up by 0.09% [3]. - The average price-to-earnings (P/E) ratios for the Shanghai Composite and ChiNext are at 14.24 and 37.51 respectively, suggesting a favorable environment for medium to long-term investments [9][10]. International Market Performance - Major international indices showed mixed results, with the Dow Jones down by 0.67% and the S&P 500 down by 0.45%, while the Nikkei 225 increased by 0.62% [4]. Industry Analysis - The AI industry is experiencing rapid growth, with significant investments in computing power infrastructure, particularly in data centers and AI servers, driven by the increasing demand for AI applications [14][25]. - The electrical equipment sector is expected to see continued valuation recovery, supported by a rebound in manufacturing activity, as indicated by a manufacturing PMI of 50.2% in February 2025 [18][20]. - The renewable energy sector, particularly wind and solar power, is witnessing increased demand, with a notable rise in installed capacity and government support for infrastructure development [36][33]. Key Economic Policies - Recent government policies aim to enhance price governance mechanisms and promote sustainable development in public utilities, which may positively impact sectors like energy and utilities [5][8]. - The National Development and Reform Commission has initiated plans to support the high-quality development of the heat pump industry, indicating a focus on energy efficiency and innovation [5][8]. Investment Recommendations - Investors are advised to focus on sectors with strong fundamentals and stable earnings, such as traditional engineering machinery and renewable energy, while also considering opportunities in emerging technologies like AI and robotics [31][35].

Group 1: Company Announcements - WuXi AppTec announced the sale of 50.8 million shares of WuXi AppTec Holdings through block trading, with a transaction amount of approximately HKD 2.178 billion, resulting in an investment gain of about RMB 1.847 billion, which accounts for over 10% of the company's latest audited net profit attributable to shareholders [1] - Jinlongyu plans to invest RMB 1.2 billion to construct a production line for key materials for solid-state batteries in Huizhou New Materials Industrial Park [2] - Dazhu CNC is conducting preliminary research on the issuance of overseas securities (H shares) and listing [3] - Anyuan Coal Industry plans to acquire 57% of Jinhui Magnetic Separation and simultaneously divest its coal business, which is expected to constitute a major asset restructuring [4] - Yuntian Lifa announced that its subsidiary has completed the delivery and acceptance of AI training and inference computing power services, positively impacting the company's operational performance [5] - AVIC Industry plans to voluntarily withdraw its A-share listing and will be suspended from trading starting April 3, 2025 [6] Group 2: Financial Performance - Naipu Mining reported a 45.46% year-on-year increase in net profit for 2024 and plans to distribute a cash dividend of RMB 0.7 per 10 shares [7] - New Hope expects a profit of RMB 430 million to RMB 500 million in the first quarter, marking a turnaround from losses [7] - Jinbei Automobile reported a net profit of RMB 382 million for 2024, a year-on-year increase of 214.06% [7] - Hailu Heavy Industry anticipates a year-on-year net profit increase of 50% to 65% for the first quarter of 2025 [8] Group 3: Major Transactions and Investments - Baiyin Nonferrous Metals completed the acquisition of a mining company's equity, increasing its copper metal resources to approximately 930,000 tons [9] - Ningbo Port expects to complete a container throughput of 12.11 million TEUs in the first quarter, a year-on-year increase of 10.9% [11] - Huafeng Communication reported a year-on-year net profit increase of 38.38% for 2024 [11] - Kid King anticipates a year-on-year net profit increase of 72.44% for 2024 and plans to distribute a cash dividend of RMB 0.5 per 10 shares [11]

2025 年 3 月 17 日，无锡药明康德新药开发股份有限公司（以下简称"公司"） 第三届董事会第十七次会议暨 2024 年年度董事会会议审议通过了《关于授权公 司投资部处置所持已上市流通股份的议案》，同意董事会授权公司投资部根据证 券市场的情况，适时择机处置公司所持已流通上市的境内外上市公司股票，出售 上述资产的总成交金额不超过公司最近一期经审计归属母公司股东净资产的 15%。授权的有效期为董事会审议通过议案之日起 12 个月或至 2025 年年度董事 会或股东大会（视届时审批权限）审议通过处置公司所持已上市流通股份议案之 日止（以孰短者为准）。具体内容请见公司于 2025 年 3 月 18 日披露的《第三届 董事会第十七次会议暨 2024 年年度董事会会议决议公告》。 公司通过间接控股子公司持有联营企业 WuXi XDC Cayman Inc.（药明合联 生物技术有限公司，以下简称"药明合联"，为香港联合交易所有限公司主板上 市公司，股份代号：2268）的股票，并已在第三届董事会第九次会议暨 2023 年 年度董事会会议审议通过的《关于授权公司投资部处置所持已上市流通股份的议 案》授权项下于 2024 ...

Core Viewpoint - WuXi AppTec's stock experienced a significant decline of 3.2% on April 2, 2023, indicating potential market concerns regarding the company's performance or external factors affecting investor sentiment [1]. Company Overview - WuXi AppTec was established in 2000 and is located in Wuxi, China, primarily engaged in research and experimental development [1]. - The company has a registered capital of 295,272.6521 million RMB, with GE LI (李革) serving as the legal representative [1]. Shareholder Information - E Fund's HuShen 300 Pharmaceutical ETF has entered WuXi AppTec's top ten shareholders, marking a new investment in the fourth quarter of the previous year [1]. - The ETF has recorded a year-to-date return of 3.75%, ranking 1143 out of 3442 in its category [1]. Fund Management - The fund manager for E Fund's HuShen 300 Pharmaceutical ETF is Yu Haiyan, who holds a master's degree in economics and has extensive experience in investment management [4][5].

Core Viewpoint - WuXi AppTec is actively advancing the construction of its Middleton facility in the U.S., with plans to commence operations by the end of 2026. The company has also announced a third round of share reduction in WuXi AppTec's subsidiary, WuXi Biologics, since November of the previous year, indicating a strategic move to enhance its global capacity and talent retention [1][3]. Group 1: Share Reduction Details - On April 1, WuXi AppTec sold 50.8 million shares of WuXi Biologics, accounting for approximately 4.23% of the total share capital, with a transaction value of about HKD 2.178 billion, representing 3.43% of the company's latest audited net assets attributable to shareholders [1][3]. - The share reduction coincided with WuXi Biologics reaching a record high stock price of HKD 49.50 per share on the same day [1]. Group 2: Financial Implications - The proceeds from the share reduction will contribute an estimated investment income of CNY 1.847 billion to WuXi AppTec's 2025 semi-annual report [3]. - In 2024, revenue from U.S. clients is projected to be CNY 25.02 billion, making up approximately 64% of the company's total revenue, highlighting the significance of the U.S. market to WuXi AppTec's financial performance [3]. Group 3: Geopolitical Considerations - The company is facing uncertainties due to the impending implementation of U.S. "reciprocal tariffs," which could impact its revenue, particularly since the U.S. is its largest market [3]. - Management has acknowledged the global nature of tariff impacts and indicated that the specific effects on the company's business remain unclear and will require further observation [3].